The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05280470
Recruitment Status : Recruiting
First Posted : March 15, 2022
Last Update Posted : April 9, 2024
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Daiichi Sankyo

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2025
Estimated Study Completion Date : June 20, 2025